S A Kaplan

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi Transurethral microwave thermotherapy for benign prostate hyperplasia: separating truth from marketing hype
    Konstantin Walmsley
    Department of Urology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Urol 172:1249-55. 2004
  2. ncbi Systematic review of the relationship between bladder and bowel function: implications for patient management
    S A Kaplan
    Weill Cornell Medical College, Cornell University, New York, NY 10021, USA
    Int J Clin Pract 67:205-16. 2013
  3. ncbi Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial
    Steven A Kaplan
    Weill Medical College of Cornell University, New York Presbyterian Hospital Weill Cornell Medical Center, NY, USA
    Eur Urol 63:158-65. 2013
  4. ncbi Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency
    Steven A Kaplan
    Weill Medical College of Cornell University, 425 East 61st St, New York, NY 10065 4805, USA
    J Urol 189:S129-34. 2013
  5. ncbi Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms
    Steven A Kaplan
    Weill Cornell Medical College, Cornell University, New York, NY 10021, USA
    BJU Int 109:1831-40. 2012
  6. ncbi Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia
    Steven A Kaplan
    Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York 10021, USA
    Urology 68:328-32. 2006
  7. ncbi Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: A landmark national US survey
    S Kaplan
    Department of Urology, Cornell University Medical Center, New York Presbyterian Hospital, Weill Cornell Medical College, Cornell University, New York, NY 10021, USA
    Int J Clin Pract 60:1157-65. 2006
  8. ncbi The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men?
    Steven A Kaplan
    Institute of Bladder and Prostrate Health, Weill Cornell Medical College, New York, New York 10021, USA
    J Urol 176:1524-7; discussion 1527-8. 2006
  9. ncbi Increased occurrence of marked elevations of lipoprotein(a) in ageing, hypercholesterolaemic men with low testosterone
    Steven A Kaplan
    Weill Cornell Medical College, Institute for Bladder and Prostate Health, New York, NY 10021, USA
    Aging Male 13:40-3. 2010
  10. ncbi Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial
    Steven A Kaplan
    Department of Urology, Weill Cornell Medical College, Cornell University, New York, NY, USA
    BJU Int 107:1432-40. 2011

Research Grants

  1. Alternative Therapies for BPH, Multiethnic Variablility
    Steven Kaplan; Fiscal Year: 2004
  2. Urodynamic and Multiethnic Variability of Men Treated b*
    Steven Kaplan; Fiscal Year: 2005

Collaborators

Detail Information

Publications80

  1. ncbi Transurethral microwave thermotherapy for benign prostate hyperplasia: separating truth from marketing hype
    Konstantin Walmsley
    Department of Urology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Urol 172:1249-55. 2004
    ..However, intense marketing and hyperbole have dominated this segment of the BPH market. Ultimately, the most effective TUMT device can only be determined by direct comparison studies...
  2. ncbi Systematic review of the relationship between bladder and bowel function: implications for patient management
    S A Kaplan
    Weill Cornell Medical College, Cornell University, New York, NY 10021, USA
    Int J Clin Pract 67:205-16. 2013
    ..In this systematic review, we discuss the relationship between bladder and bowel function and its implications for managing coexisting constipation and overactive bladder (OAB) symptoms...
  3. ncbi Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial
    Steven A Kaplan
    Weill Medical College of Cornell University, New York Presbyterian Hospital Weill Cornell Medical Center, NY, USA
    Eur Urol 63:158-65. 2013
    ..Alpha blockers are prescribed to manage lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Antimuscarinics are prescribed to treat overactive bladder (OAB)...
  4. ncbi Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency
    Steven A Kaplan
    Weill Medical College of Cornell University, 425 East 61st St, New York, NY 10065 4805, USA
    J Urol 189:S129-34. 2013
    ..Efficacy of solifenacin plus tamsulosin vs placebo plus tamsulosin was also evaluated...
  5. ncbi Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms
    Steven A Kaplan
    Weill Cornell Medical College, Cornell University, New York, NY 10021, USA
    BJU Int 109:1831-40. 2012
    ....
  6. ncbi Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia
    Steven A Kaplan
    Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York 10021, USA
    Urology 68:328-32. 2006
    ..To evaluate the efficacy and safety of nighttime dosing with tolterodine extended release (TER) in men with overactive bladder (OAB) and nocturia...
  7. ncbi Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: A landmark national US survey
    S Kaplan
    Department of Urology, Cornell University Medical Center, New York Presbyterian Hospital, Weill Cornell Medical College, Cornell University, New York, NY 10021, USA
    Int J Clin Pract 60:1157-65. 2006
    ..These findings demonstrate significant differences between the beliefs and attitudes of patients and physicians towards EP...
  8. ncbi The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men?
    Steven A Kaplan
    Institute of Bladder and Prostrate Health, Weill Cornell Medical College, New York, New York 10021, USA
    J Urol 176:1524-7; discussion 1527-8. 2006
    ..We examined pooled baseline data from 2 lipid treatment studies to evaluate the relationship among total serum testosterone levels, obesity and the metabolic syndrome in aging men...
  9. ncbi Increased occurrence of marked elevations of lipoprotein(a) in ageing, hypercholesterolaemic men with low testosterone
    Steven A Kaplan
    Weill Cornell Medical College, Institute for Bladder and Prostate Health, New York, NY 10021, USA
    Aging Male 13:40-3. 2010
    ..We further examined baseline data from a subset of US men participating in one of these two studies to assess the relationship between T and the cardiovascular risk factor lipid, lipoprotein(a) [Lp(a)]...
  10. ncbi Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial
    Steven A Kaplan
    Department of Urology, Weill Cornell Medical College, Cornell University, New York, NY, USA
    BJU Int 107:1432-40. 2011
    ..To show the superior efficacy of fesoterodine over tolterodine extended release (ER) in a placebo-controlled overactive bladder (OAB) trial with predefined treatment comparisons for both diary measures and patient-reported outcomes...
  11. ncbi Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes
    Steven A Kaplan
    Department of Urology, Weill Cornell Medical College, New York, New York 10065, USA
    Aging Male 13:100-7. 2010
    ..We present a post hoc analysis of PRO-based findings from the subset of men (without presumed bladder outlet obstruction [BOO]) from two large, independent, open-label trials of solifenacin...
  12. ncbi Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency
    Steven A Kaplan
    Weill Medical College of Cornell University, New York, New York 10065 4805, USA
    J Urol 182:2825-30. 2009
    ..Efficacy of solifenacin plus tamsulosin vs placebo plus tamsulosin was also evaluated...
  13. ncbi Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score
    Steven A Kaplan
    Department of Urology, Weill Cornell Medical College, New York, NY 10021, USA
    BJU Int 102:1133-9. 2008
    ....
  14. ncbi Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial
    Steven A Kaplan
    Department of Urology, Weill Cornell Medical College, New York, NY 10021, USA
    JAMA 296:2319-28. 2006
    ..Men with overactive bladder and other lower urinary tract symptoms may not respond to monotherapy with antimuscarinic agents or alpha-receptor antagonists...
  15. ncbi PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer
    Steven A Kaplan
    Weill Cornell Medical College, New York, New York 10021, USA
    Urology 73:935-9. 2009
    ....
  16. ncbi Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia
    Steven A Kaplan
    Department of Urology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    J Urol 174:2273-5. discussion 2275-6. 2005
    ....
  17. ncbi Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms
    Steven A Kaplan
    Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY 10021, USA
    BJU Int 103:48-57. 2009
    ..Likewise, understanding that the impact of LUTS on HRQL and the degree of bother, rather than the frequency of LUTS, are significant drivers for treatment seeking might aid in assisting patients to make decisions about treatment...
  18. ncbi Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial
    Steven A Kaplan
    Weill Cornell Medical College, New York, New York 10021, USA
    J Urol 180:1030-2; discussion 1032-3. 2008
    ....
  19. ncbi Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health
    Steven A Kaplan
    Columbia University, New York, NY, USA
    BJU Int 97:559-66. 2006
    ..Increasing clinical evidence attests to the effectiveness of doxazosin in relieving ED, even in patients refractory to ED-specific treatment, as well as in reducing BPH symptoms and elevated blood pressure...
  20. ncbi Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review
    S A Kaplan
    Department of Urology, Weill Cornell Medical College, Cornell University, New York, NY 10021, USA
    Int J Clin Pract 65:487-507. 2011
    ..Monitoring men for AUR is recommended, especially those at increased risk, and particularly within 30 days after starting antimuscarinic treatment...
  21. ncbi Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial
    Steven A Kaplan
    Weill Cornell Medical College, Cornell University, 1300 York Ave, F9 West, Box 261, New York, New York 10021, USA
    J Urol 185:1369-73. 2011
    ....
  22. ncbi Open to debate. The motion: PDE5 inhibitors will have a significant role in the treatment of BPH
    Steven A Kaplan
    Institute of Bladder and Prostate Health, Weill Cornell Medical College, Cornell University, New York, USA
    Eur Urol 52:1523-7. 2007
  23. ncbi Urinary retention and post-void residual urine in men: separating truth from tradition
    Steven A Kaplan
    Department of Urology, Weill Medical College, Cornell University, New York, New York 10021, USA
    J Urol 180:47-54. 2008
    ....
  24. ncbi [The role of muscarinic receptor antagonists in the treatment of men with lower urinary tract symptoms secondary to BPH]
    Steven A Kaplan
    Departament of Urology, Institute of Bladder and Prostate Health, Weill Cornell Medical College, New York, NY 10021, USA
    Actas Urol Esp 31:86-91. 2007
    ....
  25. ncbi Elevated high sensitivity C-reactive protein levels in aging men with low testosterone
    Steven A Kaplan
    Cornell University, New York, NY 10021, USA
    Aging Male 13:108-12. 2010
    ..We examined baseline data from a lipid treatment study to assess the relationship between testosterone (T) and the cardiovascular inflammatory marker, high sensitivity C-reactive protein (hsCRP)...
  26. ncbi Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction
    Steven A Kaplan
    Department of Urology, Weill Cornell Medical College, New York, NY, USA
    Eur Urol 51:1717-23. 2007
    ....
  27. ncbi 5alpha-reductase inhibitors: what role should they play?
    S A Kaplan
    Department of Urology, Columbia University, New York, New York, USA
    Urology 58:65-70; discussion 70. 2001
    ..Baseline parameters, such as prostate volume, prostate-specific antigen values, and whether to administer finasteride in combination with alpha blockers, are among the factors that will determine the appropriateness of such therapy...
  28. ncbi Detrusor contraction duration may predict response to alpha-blocker therapy for lower urinary tract symptoms
    S A Kaplan
    Department of Urology, Columbia Presbyterian Medical Center, New York, NY 10032, USA
    Eur Urol 37:314-7. 2000
    ....
  29. ncbi Use of prostatic stents for the treatment of benign prostatic hyperplasia in high-risk patients
    J S Lam
    Department of Urology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Curr Urol Rep 2:277-84. 2001
    ..This report reviews the current use of prostatic urethral stents in the treatment of high-risk surgical patients with BPH...
  30. ncbi Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH
    C G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9910, USA
    Prostate Cancer Prostatic Dis 14:143-8. 2011
    ..75 times those for RE- patients (P=0.0127). Absence of seminal emission may predict superior treatment efficacy of silodosin in individual patients...
  31. ncbi Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia
    S A Kaplan
    Columbia Presbyterian Medical Center, New York, New York 10032, USA
    Urology 57:1073-7. 2001
    ..In addition, the safety profile of finasteride in both older and younger men is similar and no drug interactions of clinical importance were observed...
  32. ncbi A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride
    S A Kaplan
    Weill Cornell Medical College, Cornell University, New York, NY, USA
    Int J Clin Pract 66:1052-5. 2012
    ..However, dutasteride resulted in significantly more sexual side effects and breast complications than finasteride...
  33. ncbi Benign prostatic hyperplasia: challenges for the new millennium
    M A Cabelin
    Department of Urology, J Bentley Squier Urological Clinic, New York Presbyterian Hospital, Columbia Medical Center, NY, USA
    Curr Opin Urol 10:301-6. 2000
    ..Long-term comparative prospective multicenter studies are needed to properly evaluate the outcomes of new technologies compared to traditional procedures that are considered standard of care...
  34. ncbi Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland
    A Shabsigh
    The Department of Urology, The College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA
    J Cell Biochem 81:437-44. 2001
    ....
  35. ncbi Holmium and interstitial lasers for the treatment of benign prostatic hyperplasia: a laser revival
    M A Volpe
    Columbia Presbyterian Medical Center, New York, NY 10032, USA
    Curr Opin Urol 11:43-8. 2001
    ..This paper will review published reports over the past year regarding these relatively new treatments...
  36. ncbi Variation in institutional review board responses to a standard protocol for a multicenter randomized, controlled surgical trial
    Brian T Helfand
    Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    J Urol 181:2674-9. 2009
    ....
  37. ncbi Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects
    Francois Giuliano
    Neuro urology unit, Department of Neurological Rehabilitation, Raymond Poincare Hospital, Garches, France
    Urology 67:1199-204. 2006
    ..PDE-5 inhibitors are the first-line treatment of choice for erectile dysfunction. When co-administered with alpha1-blockers, PDE-5 inhibitors could induce orthostatic hypotension...
  38. ncbi Metabolic dysfunction and male pelvic health
    Steven A Kaplan
    Eur Urol 52:316-7. 2007
  39. ncbi Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms
    Eric S Rovner
    Department of Urology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    J Urol 180:1034-41. 2008
    ....
  40. ncbi Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence
    Claus G Roehrborn
    The University of Texas Southwestern Medical Center, Dallas, TX 75390 911, USA
    BJU Int 97:1003-6. 2006
    ..They found that it significantly reduced incontinent episodes and improved patient perception of treatment benefit in men with an overactive bladder..
  41. ncbi Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men
    Steven A Kaplan
    Diabetes Care 29:749; author reply 749-50. 2006
  42. ncbi Medical therapy for asymptomatic men with benign prostatic hyperplasia: primum non nocere
    Steven A Kaplan
    Urology 62:784-5. 2003
  43. ncbi Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual function
    Steven A Kaplan
    Department of Urology, Columbia-Presbyterian Medical Center, New York, New York 10032, USA
    Urology 63:428-34. 2004
  44. ncbi PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study
    Steven A Kaplan
    Department of Urology, Columbia-Presbyterian Medical Center, New York, New York 10032, USA
    Urology 60:464-8. 2002
    ....
  45. ncbi Andropause: endocrinology, erectile dysfunction, and prostate pathophysiology
    Steven A Kaplan
    J Urol 173:2058-9. 2005
  46. ncbi The relation of lower urinary tract symptoms with life-style factors and objective measures of benign prostatic enlargement and obstruction: an Italian survey
    Steven A Kaplan
    J Urol 173:2058. 2005
  47. ncbi Transurethral resection of the prostate: the new old standard
    Joe O Littlejohn
    Department of Urology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Curr Opin Urol 12:19-23. 2002
    ....
  48. ncbi Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia
    Steven A Kaplan
    J Urol 174:1011. 2005
  49. ncbi Induction and function of CYR61 (CCN1) in prostatic stromal and epithelial cells: CYR61 is required for prostatic cell proliferation
    Steven A Kaplan
    J Urol 174:1012. 2005
  50. ncbi Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater
    Steven A Kaplan
    Columbia University Medical Center, New York, New York, USA
    J Urol 175:217-20; discussion 220-1. 2006
    ..We examined data from the Medical Therapy of Prostatic Symptoms trial to determine the relationship between baseline TPV and the effect of medical therapy in men with LUTS secondary to BPH...
  51. ncbi Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia
    Steven A Kaplan
    Department of Urology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Urology 67:225-31. 2006
  52. ncbi The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
    John D McConnell
    University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA
    N Engl J Med 349:2387-98. 2003
    ..Combination therapy and finasteride alone reduced the long-term risk of acute urinary retention and the need for invasive therapy...
  53. ncbi Do urological symptoms cluster among women? Results from the Boston Area Community Health Survey
    Susan A Hall
    New England Research Institutes, Watertown, MA 02472, USA
    BJU Int 101:1257-66. 2008
    ....
  54. ncbi Beyond the cluster: methodological and clinical implications in the Boston Area Community Health survey and EPIC studies
    Raymond C Rosen
    New England Research Institutes, Watertown, MA 02472, USA
    BJU Int 101:1274-8. 2008
    ....
  55. ncbi Are stents still a useful therapy for benign prostatic hyperplasia?
    Jason S Ogiste
    Department of Urology, Columbia University College of Physicians and Surgeons, 161 Fort Washington Avenue, New York, NY 10032, USA
    Curr Opin Urol 13:51-7. 2003
    ....
  56. ncbi Transurethral resection of the prostate--is our gold standard still a precious commodity?
    Steven A Kaplan
    J Urol 180:15-6. 2008
  57. ncbi Cluster analysis and lower urinary tract symptoms in men: findings from the Boston Area Community Health Survey
    Amy Cinar
    New England Research Institutes, Watertown, MA 02472, USA
    BJU Int 101:1247-56. 2008
    ..To classify lower urinary tract symptoms (LUTS) in a large, representative sample of men in the USA by means of cluster analysis and to investigate risk factors and comorbidities associated with the resulting cluster patterns...
  58. ncbi Commentary on holmium laser enucleation versus TURP
    Steven A Kaplan
    J Urol 179:S91. 2008
  59. ncbi Benign prostatic hyperplasia: patient perceptions and financial reality regarding the aging American prostate
    Steven A Kaplan
    J Urol 173:1852. 2005
  60. ncbi High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates
    Jaspreet S Sandhu
    Department of Urology, New York Presbyterian Hospital Cornell University Weill Medical College, New York, New York 10021, USA
    Urology 64:1155-9. 2004
    ..CONCLUSIONS: Photoselective laser vaporization of the prostate is safe and efficacious, with durable results for men with symptomatic benign prostatic hyperplasia and large-volume prostates...
  61. ncbi Benign prostatic hyperplasia: now we can begin to tailor treatment
    Carl K Gjertson
    Department of Urology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Cleve Clin J Med 71:857, 860, 863-5 passim. 2004
    ..We present an update on treatment options and a diagnostic and treatment algorithm for this condition...
  62. ncbi Long-term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia results at three months through four years
    Bruce J Trock
    Division of Epidemiology, Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    Urology 63:716-21. 2004
    ..The level of improvement for all three measures remained high at 48 months, indicating that the response is durable...
  63. ncbi Changing aspects in the evaluation and treatment of patients with benign prostatic hyperplasia
    John S Lam
    Department of Urology, David Geffen School of Medicine, 10833 Le Conte Avenue, 66-128 CHS, Box 951738, Los Angeles, CA 90095-1738, USA
    Med Clin North Am 88:281-308. 2004
    ..Fortunately, a variety of effective medical and surgical treatments are available to treat this common disease...
  64. ncbi Benign prostatic hyperplasia management--statistical significance may not translate into clinical relevance
    Steven A Kaplan
    J Urol 171:1207-8. 2004
  65. ncbi A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome
    Steven A Kaplan
    Department of Urology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Urol 171:284-8. 2004
    ..This study was designed to assess the safety and efficacy of saw palmetto or finasteride in men with category III prostatitis/chronic pelvic pain syndrome (CP/CPPS)...
  66. ncbi Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial
    Oliver M Bautista
    George Washington University, The Biostatistics Center, Rockville, MD 20852, USA
    Control Clin Trials 24:224-43. 2003
    ....
  67. ncbi An unexpected association between urinary incontinence, depression and sexual dysfunction
    Joe O Littlejohn
    Columbia-Presbyterian Medical Center, 161 Fort Washington Avenue, New York, NY 10032, U.S.A
    Drugs Today (Barc) 38:777-82. 2002
    ..There is only empiric evidence that serotonin plays a role in some types of sexual dysfunction. However, the possibility of this connection between such distinct disorders is fodder for theoretic conjecture...
  68. ncbi Are indications for prostatectomy in octogenarians the same as for younger men?
    Steven A Kaplan
    J Urol 173:2059. 2005
  69. ncbi Correlation between lower urinary tract symptoms and urethral function in benign prostatic hyperplasia
    Steven A Kaplan
    J Urol 174:1010-1. 2005
  70. ncbi Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia
    Steven A Kaplan
    J Urol 174:1904-5. 2005
  71. ncbi Male pelvic health: a urological call to arms
    Steven A Kaplan
    J Urol 176:2351-2. 2006
  72. ncbi Antimuscarinic therapy in men with bladder outlet obstruction
    David R Staskin
    Curr Urol Rep 7:437-9. 2006
  73. ncbi Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
    Ricardo R Gonzalez
    Weill Medical College of Cornell University, Institute for Bladder and Prostate Health, New York, NY 10021, USA
    Expert Opin Drug Metab Toxicol 2:609-17. 2006
    ..The ability to treat both BPH and ED with one medication is noteworthy given the significant negative impact in quality-of-life measures these disorders have in ageing men. Careful patient selection and further trials are warranted...
  74. ncbi Voiding symptom evaluation: it is time to recalibrate
    Steven A Kaplan
    Eur Urol 51:302-3. 2007
  75. ncbi First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?
    Ricardo R Gonzalez
    Institute for Bladder and Prostate Health, Weill Medical College of Cornell University, New York, NY, 10021, USA
    World J Urol 24:360-6. 2006
    ..Novel approaches to BPH management are discussed. In all cases, the risks and benefits of each treatment need to be considered and discussed with the patient; the decision is ultimately up to the patient and his urologist...
  76. ncbi Management of chronic prostatitis/chronic pelvic pain syndrome: an evidence-based approach
    Jordan D Dimitrakov
    Harvard Urological Diseases Research Center, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 67:881-8. 2006
  77. ncbi Photoselective laser vaporization prostatectomy in men receiving anticoagulants
    Jaspreet S Sandhu
    Department of Urology, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, New York 10021, USA
    J Endourol 19:1196-8. 2005
    ..CONCLUSIONS: Photoselective laser vaporization prostatectomy is a suitable treatment option in men being treated with anticoagulants, who are at high risk for clinically significant bleeding...
  78. ncbi Patients with a large prostate show a higher prevalence of androgenetic alopecia
    Steven A Kaplan
    J Urol 174:1905. 2005
  79. ncbi Three-dimensional ultrasonography in evaluation of benign prostatic hyperplasia
    Steven A Kaplan
    J Urol 174:1904. 2005
  80. ncbi Is the higher prevalence of benign prostatic hyperplasia related to lower urinary tract symptoms in Korean men due to a high transition zone index?
    James Choi
    Department of Urology, The College of Physician and Surgeons of Columbia University, New York, NY 10032, USA
    Eur Urol 42:7-11. 2002
    ....

Research Grants3

  1. Alternative Therapies for BPH, Multiethnic Variablility
    Steven Kaplan; Fiscal Year: 2004
    ..forms of BPH resulting in different rates of progression and differential response to therapy? and, D) whether concomitant prostate conditions such as prostatitis are effected by phytotherapeutic intervention for BPH? ..
  2. Urodynamic and Multiethnic Variability of Men Treated b*
    Steven Kaplan; Fiscal Year: 2005
    ..Baseline urodynamic parameters which may predict improved outcome after MIST 3. The success of various types of MIST in treating BPH in African - American, Hispanic and Caucasian men. ..